Kornimate/medical-research-clean huggingface dataset:
effect of massage and hydrotherapy to improve well-being and pain perception in endometriosis patients

Conditions: Endometriosis; Chronic Pelvic Pain Syndrome

Summary: the objective is to analyze the short-term effect of a comprehensive hammam experience combining therapeutic hydrotherapy, aromatherapy, music therapy, and swedish massage on objective parameters and patient-reported outcomes related to well-being generation and pain reduction in women with endometriosis-related chronic pelvic pain.

the main objective of this project is to analyze the short-term effect of a comprehensive hammam experience combining therapeutic hydrotherapy, aromatherapy, music therapy, and swedish massage on objective parameters and patient-reported outcomes related to well-being generation and pain reduction in women with endometriosis-related chronic pelvic pain (cpp). for this purpose, a two-arm pre-post intervention study will be conducted, randomizing 44 women with cpp (22 in the intervention group and 22 in the control group). the intervention group, in addition to following the treatment proposed by their gynecologist, will participate in a comprehensive hammam experience consisting of 3 sessions (one session each 14 days), where they will undergo a 75-minute thermal circuit (cold, warm and hot water pools) and a 15-minute of swedish massage with a special focus in the abdomino-lumbo-pelvic region. during the last session, massage will be precceded by a 15-min traditional kessa massage. during kessa massage, women will lie on a hot stone table for 15 minutes, while the skin is covered with red grape soap suds and scrubbed with a cotton fiber glove (kessa). the scrubbing will cleanse the skin of any dirt and residues, which may help them achieve a fully relaxed feeling as participants in the intervention group, those in the the control group will receive the treatment stipulated by their gynecologist. participants will be evaluated before the start of the intervention (t0), and at the end of the last session (t1) on both self-reported variables (subjective well-being scale, satisfaction with life scale, quality of life, pain intensity, pain interference and pain catastrophizing scale), and objective variables (pressure pain thresholds). treatment efficacy will be analyzed using ancova through spss v24.0 software.

Eligibility criteria:
inclusion criteria: * pelvic pain during the last 6 months more or equal to 4 in a nrs scale. * diagnosed with endometriosis (through surgery, magnetic resonance imaging or ultrasound imaging) * premenopausal status * be able to walk without assistance and to read and write enough * be capable and willing to provide consent exclusion criteria: * acute or terminal illness * a recent fracture in any upper or lower extremity (\<3 months), disc herniation and any chronic disease or orthopaedic issues that would interfere with her ability to participate in this intervention program * express unwillingness to complete the study requirements * be involved in other rehabilitation program
network support for treatment of alcohol dependence

Conditions: Alcohol Dependence

Summary: relapse is the most serious problem in alcoholism treatment. the overall aim of the present study was to determine if a treatment directed at changing the patient's social network, from one that reinforces drinking behavior to one that reinforces sobriety, can create the conditions necessary for long-term treatment success. in addition, we intended to determine if explicit reinforcement for this change of social network (contingency management or contm) would be more effective than the same network support intervention without contingent reinforcement for change.


Eligibility criteria:
inclusion criteria: * meet dsm-iv criteria for alcohol dependence * at least 18 years old * willing to accept random assignment to treatment conditions exclusion criteria: * acute medical or psychiatric problems that require inpatient treatment * reading ability below the fifth grade level * lack of reliable transportation to the treatment site * excessive commuting distance to site * current dependence on drugs (except marijuana)

Keywords: network support aa contingency management
non-interventional f-two isoprostane trial (nifti)

Conditions: Traumatic Brain Injury

Summary: each year in the united states alone, 300,000 persons are hospitalized for traumatic brain injury, with approximately one quarter dying. despite advances in aggressive neurosurgical interventions, intensive care monitoring and overall supportive management, many of those who do "survive" do not fully recover and are left with a varying degree of permanent disability. it is therefore imperative that new methods of early interventions be explored. one possible road to effective therapy is to examine the timing of secondary injury via a biological marker, to help guide the timing of treatment directed specifically at early oxidant injury. a more thorough understanding of how quickly oxidant injury occurs will allow us to direct appropriate therapies targeted directly at oxidant injury within what is currently thought to be a very narrow window of opportunity for intervention, possibly peaking within the first two hours after the initial injury. potential participants include patients between the ages of 18 and 50 years who are admitted to parkland memorial hospital with a diagnosis of severe traumatic brain injury. blood, urine, and csf (if patient requires a clinically indicated ventriculostomy) will be collected over the first 5 days post-injury. clinically-relevant patient progress, clinically required interventions, neuro-imaging results, and demographics will be tracked while the patient is hospitalized, with final neurological outcome measured at 3 months.


Eligibility criteria:
inclusion criteria: 1. estimated age of 18 - 50 years 2. glasgow come scale (gcs) score of between 3 and 8 prior to intubation and/or sedation. 3. systolic blood pressure of \>90 mm hg 4. receiving medical treatment in the emergency department (ed) of parkland hospital, a level i trauma center in dallas, texas exclusion criteria: 1. those in whom the time of injury is unknown 2. those with any 2 readings of systolic blood pressure of \<90 prior to enrollment 3. those who are known to have legal do not resuscitate (dnr) orders in place prior to enrollment. 4. those receiving cpr prior to enrollment 5. known incarcerated individuals 6. pulse ox reading of \< 90 prior to enrollment 7. status epilepticus prior to enrollment 8. penetrating head trauma
association between microbiome and the efficacy and safety of pd-1/pd-l1 blockade in resectable nsclc

Conditions: Lung Cancer (NSCLC)

Summary: this study will investigate the relationship between respiratory and gut microbiome and pd-1/pd-l1 immune checkpoint inhibitor efficacy and immune-related adverse events (irae) in patients with non-small cell lung cancer (stage iia-iiib）


Eligibility criteria:
inclusion criteria: * 18-75 years old; * first-diagnosed, driver gene-negative non-small cell lung cancer patients with histopathological confirmed diagnosis (stage iia-iiib); * at least 1 measurable lesion as defined by recist version 1.1; an eastern cooperative oncology group (ecog) physical status score of 0-1; * no prior systemic therapy or radiotherapy; * the patients are eligible for indications for surgical resection and amenable to - neoadjuvant immunotherapy or chemotherapy after multidisciplinary evaluation; * signing the written consent before enrollment in the study; * participants need to have adequate pulmonary ventilation and diffusion function to allow surgical resection by pre-enrolment pulmonary function testing; exclusion criteria: * refusal of participation or inability to give a clear consent; * requiring treatment with systemic glucocorticoids and other - immunosuppressive agents; * use of antibiotics within the previous 3 months or the presence of an infectious disease requiring antibiotic therapy; * probiotics within 3 months prior to enrolment; * presence of obstructive pneumonia, cancerous cavities, active tuberculosis; * the presence of bronchiectasis, combined lung infections, pulmonary fibrosis, uncontrolled diabetes mellitus; * the presence of primary tumors elsewhere; * receiving chemotherapy or any other cancer treatment prior to enrolment; * participants with brain metastases confirmed by brain mri with contrast prior to enrolment; * active or pre-existing autoimmune disease; * the presence of uncontrolled comorbidities, including heart failure, uncontrolled hypertension, unstable angina, interstitial lung disease; * positive test for hepatitis b surface antigen or hepatitis c ribonucleic acid requiring treatment; * known positive history or positive test results for human immunodeficiency virus or acquired immunodeficiency syndrome (aids); * history of allergy to study drug components; * women who are pregnant or breastfeeding; * previous treatment with anti-pd-1, anti-pd-l1, anti-pdl-2, or anti-ctla-4 antibodies.
investigating hd-tdcs in improving word finding and memory retrieval in individuals with mci

Conditions: Mild Cognitive Impairment

Summary: this study is attempting to improve word finding and memory retrieval problems persons with mild cognitive impairment (mci) may have.

this study attempts to improve word finding and memory retrieval problems in persons with mild cognitive impairment (mci). to remember and find words, the brain has to search for the correct memory and mci can negatively affect this search. studies have suggested that low level electrical stimulation of the memory retrieval circuit can improve memory recall. the purpose of this study is to find the exact influence of multi-electrode or high definition transcranial direct current stimulation (hd-tdcs) by targeting a frontal and a parietal brain area, and their roles in memory retrieval/word finding in mci. by modulating ongoing activity in 6 sessions of hd-tdcs the study investigates whether hd-tdcs may be used as a way to improve memory retrieval/word finding evaluated by cognitive measures and electroencephalography (eeg) measures before the first session and after the last session of hd-tdcs with a follow-up session 1-month after the stimulation procedure.

Eligibility criteria:
inclusion criteria: 1. age between 40 and 90 2. capable of understanding and signing an informed consent 3. experiencing severe memory problems exclusion criteria: 1. severe organic co-morbidity 2. pace maker / defibrillator 3. pregnancy

Keywords: high definition transcranial direct stimulation mild cognitive impairment memory
type and frequency of nasal irrigation in rhinosinusitis patients

Conditions: Otorhinolaryngologic Diseases; Rhinosinusitis

Summary: rhinosinusitis is a common clinical problem with significant morbidity which alters patients' quality of life that has its effect on 1 out of 7 adults. it has been found that rhinosinusitis accounts for almost 26 million clinics and emergency visits per year in united states .nasal irrigation is standard management used to treat a variety of sinonasal diseases. furthermore, nasal irrigation decreases the need of usage other medications in rhinosinusitis .hence, it is considered safe, inexpensive, and easy to use with no evidence of major adverse effects .up to our knowledge, there is no clear guideline in which type (isotonic saline vs hypertonic saline) and frequency (times per day) of nasal irrigation are superior and better.

nasal irrigation is one of the main treatment of sinonasal diseases. the mechanism of action of nasal irrigation has many physiological aspects such as removing of excess mucus which is a potential medium for bacterial growth and infection, cleaning of antigens and biofilm to decrease inflammatory process, increase mucocilliary function and removing curst and debris from post-surgery to enhance wound healing and mucosalization hypertonic saline is defined as a solution with more than 0.9% weight per volume of sodium chloride while isotonic saline is defined as a solution that equals to 0.9% weight per volume of sodium chloride. there are controversial studies in the literature on which saline is superior on the other, some prefer hypertonic saline over isotonic saline because it can move water outside the cells, decrease edema of mucosa, increase hydration of sol layer and decrease muco-adhesiveness and improve mucociliary clearance while others found both solution had same efficacy, improved nasal stuffiness and nasal obstruction but patients prefer isotonic saline because it is well tolerated and less burning sensation. frequency of nasal irrigation per day is poorly studied in the literature with no known recommended times per day. our aim is to find which type of saline and number of irrigation per day are better and statistically significant .

Eligibility criteria:
inclusion criteria: * age from 18 years of either gender * acute and chronic rhinosinusitis exclusion criteria: * history of nasal or sinus surgery * age less than 18 years of either gender * diagnosis other than rhinosinusitis
a pilot trial of pediatric liver transplantation without steroids

Conditions: Evidence of Liver Transplantation

Summary: objective: the overall objective is to investigate whether a steroid free immunosuppressive regimen is as safe and effective as a steroid containing regimen following pediatric liver transplantation and whether it promotes tolerance.

3.2 research question is it possible to avoid the use of corticosteroids in pediatric liver transplantation? 3.3 trial objectives this will be a pilot study to i) investigate to what degree a steroid free immunosuppressive regimen is as safe and effective as a steroid containing regimen following pediatric liver transplantation ii) investigate the effect of a steroid free immunosuppressive regimen on lymphocyte function and donor-specific immune responsiveness following pediatric liver transplantation iii) investigate the effect of a steroid free immunosuppressive regimen on expression of tissue markers of tolerance following pediatric liver transplantation it is hoped that this pilot study will be used to develop a definitive multicentre study of a steroid free regimen.

Eligibility criteria:
inclusion criteria: * children undergoing primary isolated hepatic transplantation. * age \<=18 years * ability to provide informed consent exclusion criteria: * children undergoing retransplantation. * transplantation for intestinal failure associated liver disease. * multi-organ transplantation. * transplantation for autoimmune liver disease. * transplantation for extra hepatic malignancy. * pre-existing need for oral steroids, or high dose inhaled steroids sufficient to require a steroid warning card.

Keywords: end stage liver disease paediatric liver transplantation steroid free immunosuppression
corimuno-19 - tocilizumab trial - toci (corimuno-toci)

Conditions: Corona Virus Infection

Summary: the overall objective of the study is to determine the therapeutic effect and tolerance of tocilizumab in patients with moderate, severe pneumonia or critical pneumonia associated with coronavirus disease 2019 (covid-19). tocilizumab (tcz) is an anti-human il-6 receptor monoclonal antibody that inhibits signal transduction by binding sil-6r and mil-6r. the study has a cohort multiple randomized controlled trials (cmrct) design. randomization will occur prior to offering tocilizumab administration to patients enrolled in the corimuno-19 cohort. tocilizumab will be administered to consenting adult patients hospitalized with corvid-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or critical pneumonia requiring mechanical ventilation. patients who will chose not to receive tocilizumab will receive standard of cares. outcomes of tocilizumab-treated patients will be compared with outcomes of standard of care treated patients as well as outcomes of patients treated with other immune modulators.


Eligibility criteria:
inclusion criteria: 1. patients included in the corimuno-19 cohort 2. patients belonging to one of the 2 following groups: * group 1: cases meeting all of the following criteria * requiring more than 3l/min of oxygen * oms/who progression scale = 5 * no non invasive ventilation or high flow * group 2: cases meeting all of the following criteria * respiratory failure and (requiring mechanical ventilation or non invasive ventilation or high flow) * who progression scale \>=6 * no do-not-resuscitate order (dnr order) exclusion criteria: * patients with exclusion criteria to the corimuno-19 cohort. * known hypersensitivity to tocilizumab or to any of their excipients. * pregnancy * current documented bacterial infection * patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: * absolute neutrophil count (anc) ≤ 1.0 x 109/l * haemoglobin level: no limitation * platelets (plt) \< 50 g /l * sgot or sgpt \> 5n
unruptured cerebral aneurysm: prediction of evolution

Conditions: Unruptured Intracranial Aneurysm

Summary: the protocol has many assets. a prospective nationwide recruitment allows for the inclusion of a large cohort of patients with uia. it will combine accurate clinical phenotyping and comprehensive imaging with cawe screening. besides, it will enable to exploit metadata and to explore new pathophysiological pathways of interest by crossing clinical, genetic, biological, and imaging information.

management of small (\<7mm) unruptured intracranial aneurysms (uia) remains controversial. previous retrospective studies have suggested that post gadolinium arterial wall enhancement (awe) of unruptured intracranial aneurysms on mr imaging may reflect aneurysm wall instability, and hence may highlight a higher risk of uia growth over time. this multicentric prospective cohort aims at exploring vessel wall imaging findings of uias with consecutive follow-up to substantiate these assumptions.the objective is to develop diagnostic and predictive tools for the risk of ia evolution. the aim is to demonstrate in clinical practice the predictive value of (awe) for uia growth. the growth will be determined by any modification of the uia measurement. both uia growth and the uia wall enhancement will be assessed in consensus by two expert neuroradiologists.the french prospective ucan project is a non-interventional international wide and multicentric prospective cohort. uia of bifurcation between 3 and 7 mm for whom a clinical and imaging follow-up without occlusion treatment was scheduled by local multidisciplinary staff will be included. extensive clinical, biological and imaging data will be recorded during a 3 years follow-up (visits at 1 and 3 years after inclusion).

Eligibility criteria:
inclusion criteria : * subject carrying unruptured, asymptomatic and untreated typical ia of bifurcation, measured on conventional imaging (mri, cta or dsa) between 3 and 7 mm of larger diameter. * ability to be followed-up during 3 years decided in consensus multidisciplinary gathering. * age \> 18 years old. exclusion criteria : * a failure to obtain informed consent * contraindications for undergoing an mri scan include : (heart pacemaker, a metallic foreign body (metal sliver) in their eye, or aneurysm clip in their brain, severe claustrophobia) * contraindications for a gadolinium contrast medium injection (:egfr below 30 ml/min/1.73 m2, previous or pre-existing nephrogenic systemic fibrosis, previous anaphylactic/anaphylactoid reaction to gadolinium containing contrast agent, acutely deteriorating renal function, pregnancy and breast-feeding) * a mycotic, fusiform-shaped, or dissecting ia, an ia in relation with an arteriovenous malformation * a family history of polycystic kidney disease, ehlers-danlos syndrome, marfan's syndrom, fibromuscular dysplasia, or moya moya disease * intra-cavernous uia because the sinus cavernous that is fulfilled with venous blood precluded a reliable assessment of aneurysmal wall enhancement (awe)

Keywords: unruptured cerebral aneurysm aneurysm prediction growth unruptured intracranial aneurysm
the clinical study of dexmedetomidine and esketamine combined infusion undergoing modified radical mastectomy

Conditions: Dexmedetomidine, Esketamine, Postoperative Pain and Recovery Quality

Summary: background: some studies have revealed that intravenous dexmedetomidine and esketamine alleviated postoperative pain and improve the quality of recovery after surgery. the investigators investigated whether co-administration dexmedetomidine and esketamine could better alleviated postoperative pain and improve the the quality of recovery after modified radical mastectomy. methods: one hundred and thirty-five women with elective modified radical mastectomy were randomly divided into 3 groups: patients in group d received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation. patients in group de1 received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively. patients in group de2 received received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively. primary outcome was the quality of recovery (qor-15) at 1 day after sugery and 3 day after sugery. the secondary outcomes included perioperative remifentanil consumption, postoperative vas pain scores, side effects such as the incidence of postoperative nausea, vomiting and bradycardia, hallucination, nightmare, as well as postoperative rescue analgesics and anti-emetics, recovery time, and extubation time.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status ⅰ- ⅱ * scheduled for elective modified radical mastectomy exclusion criteria: * severe respiratory disease * renal or hepatic insufficiency * history of preoperative psychiatric * preoperative bradycardia * preoperative atrioventricular block * preoperative hypertension * bmi\>30

Keywords: dexmedetomidine esketamine pain recovery quality
a comparison of bile duct injuries following open cholecystectomy versus laparoscopic cholecystectomy

Conditions: Cholecystectomy; Common Bile Duct Diseases; Major Bile Duct Injury

Summary: in this prospective study the investigators compared common bile duct injuries (cbdi) following laparoscopic cholecystectomy (lc) and open cholecystectomy (oc) procedures, 35 patients in each group. to date, no detailed study concerning this matter has been published. lc - cbdi in comparison with oc - cbdi more often concerned young females with a narrow cbd, they were located closer to the liver hilus, and they were more extended.


Eligibility criteria:
inclusion criteria: * major common bile duct injury exclusion criteria: * minor common bile duct injury